3768 EXPERIMENTAL AND THERAPEUTIC MEDICINE 14: 3768-3773, 2017 Contrast‑enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non‑small cell lung cancer NA LI1*, LU HAN1* and HUI JING2 1Department of Ultrasound, General Hospital of Daqing Oilfield, Daqing, Heilongjiang 163000; 2Department of Ultrasound, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China Received March 9, 2016; Accepted March 3, 2017 DOI: 10.3892/etm.2017.4933 Abstract. Non-small cell lung cancer (NSCLC) initiates in the administrated with nanoscale microbubble enhanced sensi- non-small cells of the lung and is one of the most common tivity and improved image quality compared with simple types of human cancer. It is known for its rapid growth, easy ultrasound. Furthermore, enhanced ultrasound resulted in a migration, invasion and reoccurrence, and has the highest inci- reliable and sensitive assessment of tumor mass in early-stage dence rate of all types of cancer. Early detection of NSCLC tumors. Altogether, contrast-enhanced ultrasound facilitated is difficult to achieve and this is the primary reason for low the efficient detection of NSCLC in patients in situ at an early survival rates in NSCLC. Contrast-enhanced ultrasound is the stage. This protocol improved the understanding of the patho- most common application for evaluating patients diagnosed physiology of NSCLC and may be applied in the detection of with NSCLC. In the present study, a contrast-enhanced ultra- early-stage tumors in patients suspected of having cancer. sound combined with nanoparticles was performed with the aim of identifying patients with NSCLC at an early stage. The Introduction present study evaluated the effectiveness of administering a nanoparticle contrast agent through respiration in combina- Lung cancer is one of the most malignant types of cancer and tion with enhanced ultrasound at improving image quality has the fastest growing incidence of 25.9 in 100,000 indi- compared with traditional ultrasound. This maybe a novel viduals and mortality rates of 22.5 in 100,000 individuals method of detecting early-stage tumors in patients. There are among all cancers (1). Lung cancer is a respiratory disease numerous benefits to conducting diagnoses of NSCLC using with higher cancer-associated mortality compared with contrast-enhanced ultrasound. It is a non-invasive imaging other types of cancer, due to worsening air conditions world- modality, induces little pain, has a low cost, an extensive wide (2). Non-small cell lung cancer (NSCLC) is the major range and produces high-resolution images. This means that form present, which is initiated in the non-small cells of the it is safer and more beneficial to use in patients with NSCLC lung and readily develops into malignant cancer that spreads than conventional imaging examinations, including X-ray throughout the body (3,4). Previous studies have demonstrated and bronchoscopy. Furthermore, the nanoscale microbubble that NSCLC has the highest incidence rate among all cancer contrast agent containing liposome-encapsulated epidermal types worldwide (5,6). It is the most common type of lung growth factor receptor was inhaled by nebulization, which cancer accounting for >80% of all lung cancer cases and may lead to an enhanced ultrasound image. The sensitivity of includes squamous cell carcinoma, large cell carcinoma and contrast-enhanced ultrasound was investigated in mice with adenocarcinoma (7-9). early stage NSCLC. The results indicated that ultrasound Although numerous studies have suggested therapeutic improvements in the treatment of NSCLC, the 5-year survival rate of patients remains very low at <15%, which is generally attributed to the high recurrent and metastatic rates (10-12). The main reason for the poor survival rate in patients is the Correspondence to: Professor Hui Jing, Department of Ultrasound, rapid migration and aggressive invasion of NSCLC cells Harbin Medical University Cancer Hospital, 150 Haping Road, during comprehensive treatment and the high likelihood of Harbin, Heilongjiang 150040, P.R. China Email: [email protected] recurrence (13,14). Conventional treatments have little efficacy against NSCLC and frequent recurrence and metastasis often *Contributed equally occurs in the clinic (14). In addition, a majority of patients with NSCLC are diagnosed with advanced stage lung cancer, which Key words: non-small cell lung cancer, contrast-enhanced influenced the effectiveness of treatments due to increased ultrasound, nanoscale microbubble apoptosis resistance and tumor metastasis (15). Therefore, identifying effective protocols to deliver an early diagnosis of NSCLC becomes a priority for researchers. LI et al: CONTRAST-ENHANCED ULTRASOUND DIAGNOSIS IN PATIENTS WITH EARLY NSCLC 3769 Early diagnosis of patients with cancer is favorable for Principles and settings of contrast‑enhanced ultrasound. The treatment, as it increases the survival time and decreases ultrasound diagnosis system analyzed contrast-enhanced the pain and the economic burden experienced by patients ultrasound clinical trials using a preprogrammed setting. with NSCLC (16). In the present study, a contrast-enhanced The preprogrammed setting was optimized to reach the best ultrasound combined with nanoparticle contrast agent was image formation. The mechanical index was set between introduced, which could potentially be applied to improve 0.2-0.4 to avoid destruction of the fragile microbubbles that imaging modality for NSCLC. This agent exhibited advan- contain nanoparticles. The details of principles and settings tages for both early diagnosis and final confirmation of of the contrast-enhanced ultrasound were as previously suspicious cases. In addition, it was concluded from previous described (22). studies that optimal therapeutic outcomes are dependent on early diagnosis and treatment (16,17). Ultrasound contrast agents. A novel ultrasound contrast agent The mechanism of ultrasound diagnosis is dependent was introduced with the aim of diagnosing NSCLC at an early on short waves that penetrate soft tissue in order to identify stage. The multi-targeted tyrosine kinase inhibitor Lenvatinib the presence of any lumps. This is achieved in tissues by (Selleck Chemicals LLC, Boston, MA, USA) was covalently the bouncing back of waves when they reach the lumps (18). bound with the nanoparticles of super paramagnetic iron Contrast-enhanced ultrasound is currently used to diagnose oxide particles as previously described (23). The nanoparticle cardiovascular conditions, as it is non-invasive, painless, ultrasound contrast agent and Optison (GE Healthcare Life relatively cheap, has an extensive range and high-resolu- Sciences, Shanghai, China) entered the lung by breathing tion (19,20). Notably, contrast-enhanced ultrasound is widely and an atomizer (GE Healthcare Life Sciences) was used to applied in the diagnosis of hypertrophic cardiomyopathy (21). ensure the entire lung was covered. Following administration Microbubbles are the most common used ultrasound contrast by respiration, the nanoparticle ultrasound contrast agent was agent and provide a strongly reflective interface and resonate distributed through the respiratory system. The microbubbles, to ultrasound waves, which are easily observed (22). In the within the nanoparticle, contained the multi-targeted tyrosine present study, an improved contrast-enhanced ultrasound kinase inhibitor Lenvatinib and Lenvatinib was capable of administrated with a nanoparticle contrast agent aimed to transporting the target to tumor cells. Furthermore, the micro- improve image quality and resolution, thus improving the bubbles targeted the lesion through the pulmonary circulation rate of early diagnosis of NSCLC compared with a standard due to their small diameter. After 30 min, the nanoparticle ultrasound. This improved the ultrasound contrast and boosted ultrasound contrast agent could be visualized using an imaging the diagnostic accuracy in patients with NSCLC compared system (General Electric GE Voluson S8; GE Healthcare Life with standard ultrasound, which may have important clinical Sciences). No side effects were observed in patients following implications. its use. Materials and methods Immunofluorescence and histological staining. Tumor cells were obtained from patients with NSCLC. The cells (1x105) Patients. A total of 302 patients with suspicious NSCLC were were cultured for 72 at 37˚C in 6‑well plates in Dulbecco's enrolled from Department of Ultrasound, General Hospital modified Eagle's minimal essential medium (Gibco; Thermo of Daqing Oilfield between January 2014 and January 2015 Fisher Scientific, Inc., Waltham, MA, USA) supplemented in the present study. The age range of patients was between with 10% heat‑inactivated fetal bovine serum (Biowhittaker; 43 and 72 years old with a median age of 52 years old and Lonza, Basel, Switzerland). The cell density was adjusted the male (148) to female (154) ratio was approximately to 5x104/ml. The cells were then incubated with primary equal. Patients suspected of having NSCLC were eligible for anti‑carcino embryonic antigen (catalogue no. ab4451; the present study. Inclusion criteria was as follows: Those Abcam, Cambridge, MA, USA) or PBS (mock group) for 12 h confirmed with NSCLC, with stage IV disease at the time of at 4˚C, then incubated with anti‑rabbit immunoglobulin (Ig) study entry, those with measurable disease at the time of study G and anti-mouse IgG (catalogue nos.